Sanofi India Limited has announced an investor and analysts call to discuss its audited financial results for the quarter and year ended December 31, 2025. The pharmaceutical company made this announcement in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Call Schedule and Access Details

The investor call is scheduled for Thursday, February 26, 2026, and will run from 4:00 PM to 5:00 PM IST. The company has arranged comprehensive access options for participants, including both domestic and international dial-in facilities.

International Access Options

Sanofi India has provided extensive international toll-free access to accommodate global investors and analysts. The company has arranged dedicated numbers for multiple countries across different continents.

Webcast and Registration Requirements

In addition to the dial-in options, Sanofi India will host a one-way audio webcast of the conference call. The company has implemented a pre-registration system to manage participant access effectively.

Key webcast details include:

• Pre-registration is mandatory for webcast participation
• Registration remains open until 12:00 PM IST on February 26, 2026
• Investors will have opportunities to view company presentations
• Question and answer sessions will follow registration sequence
• Management interaction will be available during the call

Regulatory Compliance

The announcement was formally communicated to both BSE Limited (Scrip Code: 500674) and The National Stock Exchange of India Limited (Symbol: SANOFI) on February 19, 2026. Company Secretary and Compliance Officer Haresh Vala (Membership No: A18246) signed the official notification, ensuring full compliance with regulatory disclosure requirements.

This investor call represents Sanofi India's commitment to maintaining transparent communication with its stakeholders regarding the company's financial performance for the concluded quarter and fiscal year.

Sanofi India Limited has announced a key change in its senior management team with the resignation of Mr. Suresh Babu, who served as Sales & Customer Engagement Head – Diabetes. The pharmaceutical company disclosed this development in compliance with regulatory requirements on February 12, 2026.

Resignation Details

Mr. Suresh Babu tendered his resignation from the services of the company effective from the close of business on February 12, 2026. The resignation was submitted to pursue other opportunities outside Sanofi, marking the end of his tenure as a Senior Management Personnel of the company.

Regulatory Compliance

The company has fulfilled its disclosure obligations under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement was made to both BSE Limited and The National Stock Exchange of India Limited, ensuring transparency with stakeholders and regulatory authorities.

Transition Process

According to the resignation correspondence, Mr. Babu initially proposed February 28 as his last working day to allow for proper handover and transition. However, the final arrangement resulted in his departure on February 12, 2026, after completing the necessary handover procedures. The departing executive expressed commitment to ensuring a smooth transition with all details for business continuity.

Corporate Documentation

The disclosure was signed by Haresh Vala, Company Secretary and Compliance Officer, and includes comprehensive documentation as required under SEBI regulations. The company has also uploaded this information on its official website for stakeholder access and transparency.